·  Evaluate the spectrum and pathophysiologic mechanisms of cardiometabolic complications associated with contemporary antiretroviral therapy (ART), including dyslipidemia, insulin resistance, weight gain, and accelerated atherosclerotic cardiovascular disease in people with chronic HIV infection.

·  Critically assess the differential cardiometabolic risk profiles of major antiretroviral classes (e.g., integrase strand transfer inhibitors, protease inhibitors, and nucleoside reverse transcriptase inhibitors) and their interaction with traditional risk factors and HIV-related inflammation.

·  Apply evidence-based strategies to mitigate cardiometabolic risk in patients on ART, including individualized regimen selection, cardiovascular risk stratification, and implementation of pharmacologic and lifestyle interventions in the context of chronic HIV care.